<DOC>
	<DOCNO>NCT00033605</DOCNO>
	<brief_summary>RATIONALE : Octreotide may effective prevent control diarrhea patient undergo radiation therapy pelvis . It yet know whether octreotide effective diarrhea . PURPOSE : Randomized phase III trial determine effectiveness octreotide prevent diarrhea patient undergo radiation therapy pelvis .</brief_summary>
	<brief_title>Octreotide Preventing Diarrhea Patients Who Are Undergoing Radiation Therapy Pelvis</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness octreotide reduce acute treatment-related diarrhea patient receive external-beam radiotherapy pelvis . - Determine effectiveness drug reduce chronic treatment-related bowel dysfunction patient . - Determine toxicity drug patient . - Assess importance patient attach various measure bowel function . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord prior anterior resection rectum ( yes v ) , total plan cumulative dose radiotherapy , include boost field ( 4,500-5,350 cGy v 5,351-6,000 cGy v 6,000 cGy ) , use concurrent fluorouracil ( none v bolus vs continuous infusion ) , use concurrent leucovorin calcium ( yes v ) , use concurrent cisplatin ( yes v ) , superior border initial field ( inferior L4-5 interspace v superior L4-5 interspace ) , plan intracavitary brachytherapy ( yes v ) , primary site disease ( rectal cancer v prostate cancer v gynecological cancer v ) . Beginning late fourth day radiotherapy , patient randomize one two treatment arm . - Arm I : Patients receive short-acting octreotide subcutaneously ( SC ) day 1 long-acting octreotide intramuscularly ( IM ) day 2 29 . - Arm II : Patients receive placebo SC day 1 IM day 2 29 . In arm , treatment continue absence unacceptable toxicity development severe diarrhea . Patients complete bowel function questionnaire baseline , weekly radiotherapy , weekly 4 week 1 2 year completion radiotherapy . Patients follow weekly 4 week 1 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cancer pelvis Plan receive continuous definitive adjuvant externalbeam radiotherapy pelvis pelvis paraaortic lymph node ( total plan dose 4,5005,350 cGy ) Entire pelvis must encompass planned radiotherapy field ( superior border inferior inferior aspect sacroiliac joint ) Portions rectum may special block depend disease site Planned treatment oncedaily radiotherapy 45 time week ( plan daily dose 170210 cGy ) No planned splitcourse radiotherapy No plan interstitial brachytherapy prior completion externalbeam radiotherapy Planned intracavitary radiotherapy allow No plan cytotoxic chemotherapy agent concurrently radiotherapy except fluorouracil without leucovorin calcium cisplatin Entered study third radiotherapy fraction No current prior metastases beyond pelvic paraaortic lymph nod No grade 3 great diarrhea , rectal bleeding , abdominal cramping prior radiotherapy No incontinence stool PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Renal : No chronic renal failure Creatinine le 2 time upper limit normal ( patient history renal disease ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known allergy octreotide No history inflammatory bowel disease No concurrent medical condition would preclude study participation No history cholecystitis unless prior cholecystectomy PRIOR CONCURRENT THERAPY : Radiotherapy : See Disease Characteristics No prior radiotherapy pelvis Surgery : See Disease Characteristics No prior abdominalperineal resection , Hartmann procedure , surgical procedure result nonfunctioning rectum</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>